Literature DB >> 21146147

Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients.

Tijana Andjelkovic1, Jasna Bankovic, Jelena Stojsic, Vedrana Milinkovic, Ana Podolski-Renic, Sabera Ruzdijic, Nikola Tanic.   

Abstract

The inactivation of p53 and PTEN tumor suppressor genes is a common genetic event in lung cancer. However, data on the effect of the joint inactivation of tumor-suppressor genes in non-small cell lung carcinoma (NSCLC) are lacking. The purpose of this study was to investigate the alterations in PTEN and p53 genes, as well as to evaluate their mutual role in NSCLC pathogenesis and their impact on survival rate. To that end, polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP), sequencing, methylation-specific PCR, and fragment analysis were used. The results obtained were correlated with clinicopathologic parameters, the level of genomic instability, and patient survival. Overall, 13% of specimens had aberrant p53 only, 13% had inactive PTEN only, and 50% of samples had both genes altered. Correlation analyses showed that the mutual inactivation of p53 and PTEN was a frequent event that was associated significantly with the increased level of genomic instability and lymph node invasion implying their synergistic effect in promoting metastatic phenotype of this kind of cancer. In addition, our results revealed a significant association of joint alterations of these genes with dramatically shortened survival indicating that aberrant p53 and PTEN could be used as an adverse prognostic factor for NSCLC patients' outcome. Our findings established the relevance of the combinatorial inactivation of p53 and PTEN in NSCLC progression and identified a subgroup of patients with a particularly aggressive disease.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146147     DOI: 10.1016/j.trsl.2010.09.004

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  14 in total

1.  Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Authors:  Miodrag Dragoj; Jasna Bankovic; Evangelia Sereti; Sofija Jovanovic Stojanov; Konstantinos Dimas; Milica Pesic; Tijana Stankovic
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

Review 2.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

3.  Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.

Authors:  Miodrag Dragoj; Zorica Milosevic; Jasna Bankovic; Nikola Tanic; Milica Pesic; Tijana Stankovic
Journal:  Cell Oncol (Dordr)       Date:  2016-11-07       Impact factor: 6.730

4.  Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1).

Authors:  Yang Jiao; Ke-kang Sun; Lin Zhao; Jia-ying Xu; Li-li Wang; Sai-jun Fan
Journal:  Acta Pharmacol Sin       Date:  2011-12-12       Impact factor: 6.150

5.  Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.

Authors:  Miodrag Dragoj; Zorica Milosevic; Jasna Bankovic; Jelena Dinic; Milica Pesic; Nikola Tanic; Tijana Stankovic
Journal:  Tumour Biol       Date:  2015-06-09

6.  Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.

Authors:  Gang Li; Jingfeng Zhao; Xianjing Peng; Jian Liang; Xin Deng; Yuxiang Chen
Journal:  Cancer Biother Radiopharm       Date:  2012-04-10       Impact factor: 3.099

7.  Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.

Authors:  Zorica Milosevic; Nikola Tanic; Jasna Bankovic; Tijana Stankovic; Marko Buta; Dragana Lavrnic; Zorka Milovanovic; Gordana Pupic; Sonja Stojkovic; Vedrana Milinkovic; Yasuhiro Ito; Radan Dzodic
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

8.  Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.

Authors:  Min Li; Huawen Sun; Lujun Song; Xiaodong Gao; Wenju Chang; Xinyu Qin
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

9.  Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus.

Authors:  Yvonne Tay; Shen Mynn Tan; Florian A Karreth; Judy Lieberman; Pier Paolo Pandolfi
Journal:  Cell Rep       Date:  2014-07-31       Impact factor: 9.423

Review 10.  Genomics of squamous cell lung cancer.

Authors:  Melissa Rooney; Siddhartha Devarakonda; Ramaswamy Govindan
Journal:  Oncologist       Date:  2013-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.